Connection

Maria Lopes-Virella to Oxidation-Reduction

Back to Details
This is a "connection" page, showing publications Maria Lopes-Virella has written about Oxidation-Reduction.
Maria Lopes-Virella
Connection Strength
0.519
Oxidation-Reduction
  1. Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010 Jan; 134(1):55-65.
    View in: PubMed
    Score: 0.070
  2. Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol. 2003 Jul; 10(4):499-505.
    View in: PubMed
    Score: 0.047
  3. Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis. 2001 Jan; 154(1):79-86.
    View in: PubMed
    Score: 0.039
  4. The preparation of copper-oxidized LDL for the measurement of oxidized LDL antibodies by EIA. Atherosclerosis. 2000 Sep; 152(1):107-15.
    View in: PubMed
    Score: 0.038
  5. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes. 2000 Jun; 49(6):1033-41.
    View in: PubMed
    Score: 0.038
  6. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol. 2000 May; 95(2):135-44.
    View in: PubMed
    Score: 0.037
  7. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1999 Jul; 48(7):1454-8.
    View in: PubMed
    Score: 0.035
  8. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999 Feb; 90(2):165-72.
    View in: PubMed
    Score: 0.034
  9. Association of apolipoprotein A phenotypes and oxidized low-density lipoprotein immune complexes in children. Arch Pediatr Adolesc Med. 1999 Jan; 153(1):57-62.
    View in: PubMed
    Score: 0.034
  10. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes. 1996 Jun; 45(6):762-7.
    View in: PubMed
    Score: 0.028
  11. Comparing assays of antibodies to modified low-density lipoproteins. Clin Chem. 1995 Feb; 41(2):324-5.
    View in: PubMed
    Score: 0.026
  12. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J. 1993 Dec; 14 Suppl K:118-24.
    View in: PubMed
    Score: 0.024
  13. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 1993; 23(2):95-101.
    View in: PubMed
    Score: 0.022
  14. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res. 2008 Apr; 49(4):847-55.
    View in: PubMed
    Score: 0.016
  15. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res. 2003 Mar; 44(3):487-93.
    View in: PubMed
    Score: 0.011
  16. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation. 2002 May 07; 105(18):e138-43.
    View in: PubMed
    Score: 0.011
  17. Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low-density lipoproteins. Clin Diagn Lab Immunol. 1998 Nov; 5(6):817-22.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.